Intra-Cellular’s Caplyta shows efficacy in late-stage schizophrenia trial
The company initially received approval for Caplyta in 2019 in the US and Study 304 is a post-marketing withdrawal trial as part of FDA's regulations for antipsychotic drugs
Uncategorized
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE
Enzian Pharmaceutics Develops a Novel Dosage Form for Enhanced Efficacy and Reduced Side Effects of Cancer Therapies
UK approves Novo Nordisk’s semaglutide to prevent cardiovascular events in obese adults
CordenPharma invests €900m to expand its peptide platform in US and Europe
Nona Bio, Alaya.bio partner to develop novel CAR-T cell therapies
Health Canada approves Tagrisso plus Chemotherapy for lung cancer
Arcutis secures FDA approval for Zoryve cream to treat atopic dermatitis
